The trim-down tactics this spring by Poniard Pharmaceuticals Inc. to pump more thrust behind the Phase III SPEAR trial put most of the company's oomph behind its "pipeline-in-a-drug" candidate picoplatin, and easily could lead to an acquisition after data roll out by the end of this year. Read More
